Bora Pharmaceuticals Future Growth
Future criteria checks 5/6
Bora Pharmaceuticals is forecast to grow earnings and revenue by 79.4% and 33.5% per annum respectively while EPS is expected to grow by 82.4% per annum.
Key information
79.4%
Earnings growth rate
82.42%
EPS growth rate
| Pharmaceuticals earnings growth | 14.9% |
| Revenue growth rate | 33.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 May 2026 |
Recent future growth updates
Recent updates
Narrative Update • Apr 28
6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power
Analysts have raised their price target on Bora Pharmaceuticals by NT$741.35, reflecting slightly higher assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing agreement, extending GSK's access to multiple Bora sites, including the Mississauga facility acquired from GSK in 2020 and the oral solid dose site in Maple Grove, Minnesota (Key Developments).Narrative Update • Apr 12
6472: Renewed GSK Manufacturing Partnership Will Support Long Term Earnings Power
Analysts have adjusted their price target on Bora Pharmaceuticals to reflect updated assumptions around revenue growth of 29.12% and a profit margin of 20.96%. The implied fair value remains around NT$741.35 based on a forward P/E of 13.69.Narrative Update • Mar 28
6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power
Analysts have inched up their price target on Bora Pharmaceuticals to NT$741.35 from NT$741.02, citing updated assumptions that combine a higher revenue growth outlook of 29.58% with a slightly stronger profit margin of 20.74% and a modestly lower future P/E of 13.69. What's in the News Bora Pharmaceuticals has scheduled a board meeting on March 11, 2026, to review the 2025 fourth quarter consolidated financial statement (Key Developments).Narrative Update • Mar 13
6472: Renewed GSK Manufacturing Alliance Will Drive Long Term Upside Potential
Analysts have kept their NT$741.02 price target for Bora Pharmaceuticals unchanged, pointing to stable views on fair value, discount rate, revenue growth assumptions, profit margins, and future P/E as the key reasons for maintaining their stance. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing partnership, extending their existing relationship and broadening GSK access to multiple Bora sites, including the oral solid dose facility in Maple Grove, Minnesota (Key Developments).Narrative Update • Feb 26
6472: Renewed GSK Partnership And Corealis Alliance Will Support Future Upside
Analysts have kept their NT$741.02 price target for Bora Pharmaceuticals unchanged, citing largely stable assumptions on the discount rate, revenue growth, profit margin, and a slightly lower future P/E multiple. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing partnership, which gives GSK access to multiple Bora sites, including the Mississauga facility acquired from GSK in 2020 and a newer oral solid dose site in Maple Grove, Minnesota (Key Developments).Narrative Update • Feb 11
6472: Corealis Alliance Will Support Future Upside Through End To End Development
Analysts have modestly adjusted their price target on Bora Pharmaceuticals to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. This has resulted in a refreshed fair value estimate of about NT$741.02 per share.Narrative Update • Jan 28
6472: Corealis Alliance Will Drive Future Upside Through Integrated Development Path
Analysts have trimmed their price target for Bora Pharmaceuticals to reflect a fair value update to $741.02 from $788.87, citing slightly adjusted revenue growth assumptions, a modestly higher profit margin outlook, and a lower future P/E input in their models. What's in the News Bora Pharmaceuticals Co., Ltd.Narrative Update • Jan 11
6472: Corealis Alliance Will Support Future Upside Through Streamlined Development
Analysts have kept their price target for Bora Pharmaceuticals broadly unchanged at about $789, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that recent research has not materially shifted their valuation view. What's in the News Bora Pharmaceuticals Co., Ltd.Narrative Update • Dec 20
6472: Alliance With Corealis Will Support Stronger Long Term Performance
Analysts have modestly reiterated their outlook on Bora Pharmaceuticals, keeping the fair value estimate steady at $788.87 per share, as they see no material changes to projected revenue growth, margins, or valuation multiples. What's in the News Bora Pharmaceuticals and Corealis Pharma formed a strategic alliance to deliver integrated end to end oral solid dose development and manufacturing services, giving clients a single pathway from early formulation through commercial production (company announcement) The partnership combines Bora's global commercial infrastructure with Corealis' formulation and clinical scale manufacturing expertise, aiming to accelerate timelines and reduce complexity for biotech and pharma innovators (company announcement) Bora and Corealis will align project management and quality systems across the drug development lifecycle to lower outsourcing risk and improve reliability from discovery through commercial launch (company announcement) Valuation Changes Fair Value Estimate is unchanged at NT$788.87 per share, indicating no revision to Bora Pharmaceuticals' intrinsic value assessment.Narrative Update • Dec 06
6472: Improved Profit Margins Will Support Stronger Long Term Performance
Narrative Update Analysts have nudged their price target on Bora Pharmaceuticals slightly higher to approximately $789 per share, reflecting modestly improved long term profit margin expectations, even though projected revenue growth has been tempered slightly. Valuation Changes Fair Value Estimate: unchanged at approximately NT$788.87 per share, indicating no material revision to the intrinsic value assessment.Narrative Update • Nov 21
6472: Improved Profit Margins Will Drive Stronger Performance Ahead
Analysts have lowered their price target for Bora Pharmaceuticals from $872.67 to $788.87. This adjustment is due to reduced revenue growth expectations, which are partially offset by projections of improved profit margins and a lower forward price-to-earnings ratio.Narrative Update • Sep 28
US CDMO Expansion And Specialty Focus Will Strengthen Position
The consensus analyst price target for Bora Pharmaceuticals has been revised upward, primarily driven by a significant increase in the company's expected future P/E multiple, with the fair value rising from NT$847.46 to NT$872.67. What's in the News Bora Pharmaceuticals is making significant investments to expand manufacturing and packaging capabilities at its Maple Grove, Minnesota facility, acquired via the $210 million Upsher-Smith Laboratories deal in 2024.New Narrative • Jul 20
US Facility Modernization Will Secure Future Specialty Success
Strategic shift to high-value CDMO services and facility upgrades has improved margins, driven growth, and positioned the company for market share gains.Analysis Article • Mar 30
Cautious Investors Not Rewarding Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Performance Completely
With a median price-to-earnings (or "P/E") ratio of close to 20x in Taiwan, you could be forgiven for feeling...Analysis Article • Jan 20
We Think Bora Pharmaceuticals (TWSE:6472) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Nov 21
Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem
Bora Pharmaceuticals Co., LTD.'s ( TWSE:6472 ) robust earnings report didn't manage to move the market for its stock...Analysis Article • Oct 04
Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Jul 18
Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects
Bora Pharmaceuticals Co., LTD.'s ( TWSE:6472 ) price-to-earnings (or "P/E") ratio of 34.2x might make it look like a...Analysis Article • Jun 13
Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?
Key Insights The projected fair value for Bora Pharmaceuticals is NT$1,369 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Apr 10
Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Bora Pharmaceuticals Co., LTD. ( TWSE:6472 ) shareholders have had their patience rewarded with a 33% share price jump...Analysis Article • Apr 08
Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Mar 14
Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality
Even though Bora Pharmaceuticals Co., LTD. ( TWSE:6472 ) posted strong earnings, investors appeared to be underwhelmed...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 32,432 | 6,821 | 5,225 | 8,843 | 3 |
| 12/31/2026 | 20,726 | 2,684 | 1,439 | 2,973 | 1 |
| 3/31/2026 | 18,536 | 1,682 | 2,656 | 3,775 | N/A |
| 12/31/2025 | 19,014 | 4,383 | 3,531 | 4,504 | N/A |
| 9/30/2025 | 21,097 | 4,242 | 2,064 | 3,032 | N/A |
| 6/30/2025 | 21,319 | 5,126 | 3,813 | 4,542 | N/A |
| 3/31/2025 | 20,868 | 5,964 | 475 | 1,089 | N/A |
| 12/31/2024 | 17,427 | 4,116 | 293 | 980 | N/A |
| 9/30/2024 | 15,508 | 4,252 | 1,827 | 2,379 | N/A |
| 6/30/2024 | 13,556 | 3,282 | -572 | 1,014 | N/A |
| 3/31/2024 | 12,277 | 2,707 | 2,306 | 3,871 | N/A |
| 12/31/2023 | 14,200 | 3,030 | 3,183 | 4,614 | N/A |
| 9/30/2023 | 16,293 | 2,868 | 2,848 | 4,257 | N/A |
| 6/30/2023 | 15,942 | 2,704 | 4,038 | 4,362 | N/A |
| 3/31/2023 | 14,158 | 2,252 | 3,684 | 3,926 | N/A |
| 12/31/2022 | 10,494 | 1,392 | 1,810 | 2,010 | N/A |
| 9/30/2022 | 6,346 | 1,128 | 1,322 | 1,465 | N/A |
| 6/30/2022 | 4,811 | 697 | 844 | 1,029 | N/A |
| 3/31/2022 | 4,650 | 594 | 1,079 | 1,389 | N/A |
| 12/31/2021 | 4,900 | 750 | 873 | 1,237 | N/A |
| 9/30/2021 | 4,418 | 1,045 | 636 | 975 | N/A |
| 6/30/2021 | 3,626 | 963 | 286 | 603 | N/A |
| 3/31/2021 | 2,794 | 868 | -261 | -43 | N/A |
| 12/31/2020 | 1,800 | 578 | 26 | 178 | N/A |
| 9/30/2020 | 1,523 | 191 | -608 | 188 | N/A |
| 6/30/2020 | 1,513 | 232 | -317 | 415 | N/A |
| 3/31/2020 | 1,521 | 262 | -211 | 478 | N/A |
| 12/31/2019 | 1,529 | 305 | N/A | 232 | N/A |
| 9/30/2019 | 1,517 | 355 | N/A | 449 | N/A |
| 6/30/2019 | 1,492 | 283 | N/A | 373 | N/A |
| 3/31/2019 | 1,515 | 267 | N/A | 318 | N/A |
| 12/31/2018 | 1,372 | 443 | N/A | 167 | N/A |
| 9/30/2018 | 1,107 | 351 | N/A | -40 | N/A |
| 6/30/2018 | 846 | 330 | N/A | -218 | N/A |
| 3/31/2018 | 525 | 274 | N/A | -263 | N/A |
| 12/31/2017 | 358 | 14 | N/A | 20 | N/A |
| 9/30/2017 | 323 | 17 | N/A | 2 | N/A |
| 6/30/2017 | 297 | 22 | N/A | 22 | N/A |
| 3/31/2017 | 291 | 24 | N/A | 5 | N/A |
| 12/31/2016 | 283 | 25 | N/A | -18 | N/A |
| 9/30/2016 | 273 | 23 | N/A | -20 | N/A |
| 6/30/2016 | 260 | 18 | N/A | -22 | N/A |
| 3/31/2016 | 247 | 26 | N/A | -4 | N/A |
| 12/31/2015 | 238 | 34 | N/A | 9 | N/A |
| 9/30/2015 | 236 | 30 | N/A | 18 | N/A |
| 6/30/2015 | 234 | 28 | N/A | 13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6472's forecast earnings growth (79.4% per year) is above the savings rate (1.3%).
Earnings vs Market: 6472's earnings (79.4% per year) are forecast to grow faster than the TW market (26.5% per year).
High Growth Earnings: 6472's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 6472's revenue (33.5% per year) is forecast to grow faster than the TW market (18.9% per year).
High Growth Revenue: 6472's revenue (33.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6472's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/23 10:27 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bora Pharmaceuticals Co., Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| Chenghsin Lin | J.P. Morgan |
| null null | KGI Securities Co. Ltd. |